JP2011518858A5 - - Google Patents

Download PDF

Info

Publication number
JP2011518858A5
JP2011518858A5 JP2011506689A JP2011506689A JP2011518858A5 JP 2011518858 A5 JP2011518858 A5 JP 2011518858A5 JP 2011506689 A JP2011506689 A JP 2011506689A JP 2011506689 A JP2011506689 A JP 2011506689A JP 2011518858 A5 JP2011518858 A5 JP 2011518858A5
Authority
JP
Japan
Prior art keywords
methyl
dihydro
methylsulfonyl
benzodioxin
amine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2011506689A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011518858A (ja
JP5514804B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2009/055137 external-priority patent/WO2009133107A1/en
Publication of JP2011518858A publication Critical patent/JP2011518858A/ja
Publication of JP2011518858A5 publication Critical patent/JP2011518858A5/ja
Application granted granted Critical
Publication of JP5514804B2 publication Critical patent/JP5514804B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2011506689A 2008-04-29 2009-04-28 ドーパミン神経伝達のモジュレーター Expired - Fee Related JP5514804B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
DKPA200800598 2008-04-29
DKPA200800598 2008-04-29
US4905908P 2008-04-30 2008-04-30
US61/049,059 2008-04-30
PCT/EP2009/055137 WO2009133107A1 (en) 2008-04-29 2009-04-28 Modulators of dopamine neurotransmission

Publications (3)

Publication Number Publication Date
JP2011518858A JP2011518858A (ja) 2011-06-30
JP2011518858A5 true JP2011518858A5 (cg-RX-API-DMAC7.html) 2012-06-14
JP5514804B2 JP5514804B2 (ja) 2014-06-04

Family

ID=40940061

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011506689A Expired - Fee Related JP5514804B2 (ja) 2008-04-29 2009-04-28 ドーパミン神経伝達のモジュレーター

Country Status (15)

Country Link
US (1) US8524766B2 (cg-RX-API-DMAC7.html)
EP (1) EP2271634B1 (cg-RX-API-DMAC7.html)
JP (1) JP5514804B2 (cg-RX-API-DMAC7.html)
KR (1) KR20100135325A (cg-RX-API-DMAC7.html)
CN (1) CN102036976B (cg-RX-API-DMAC7.html)
AU (1) AU2009242092A1 (cg-RX-API-DMAC7.html)
BR (1) BRPI0911772A2 (cg-RX-API-DMAC7.html)
CA (1) CA2722978A1 (cg-RX-API-DMAC7.html)
DK (1) DK2271634T3 (cg-RX-API-DMAC7.html)
IL (1) IL208289A0 (cg-RX-API-DMAC7.html)
MX (1) MX2010011724A (cg-RX-API-DMAC7.html)
NZ (1) NZ588209A (cg-RX-API-DMAC7.html)
RU (1) RU2010141964A (cg-RX-API-DMAC7.html)
WO (1) WO2009133107A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201006932B (cg-RX-API-DMAC7.html)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2271635A1 (en) * 2008-04-29 2011-01-12 NSAB, Filial af NeuroSearch Sweden AB, Sverige Modulators of dopamine neurotransmission
AU2009242095A1 (en) * 2008-04-29 2009-11-05 Nsab, Filial Af Neurosearch Sweden Ab, Sverige Modulators of dopamine neurotransmission
CN102180856B (zh) * 2011-03-01 2016-01-20 浙江华海药业股份有限公司 一种制备6-氟-3,4-二氢-2h-1-苯并吡喃-2-甲酸乙酯的方法
SG193992A1 (en) 2011-04-19 2013-11-29 Integrative Res Lab Sweden Ab Novel modulators of cortical dopaminergic- and nmda-receptor-mediated glutamatergic neurotransmission
KR20160027217A (ko) 2012-05-23 2016-03-09 에프. 호프만-라 로슈 아게 내배엽 및 간세포를 수득하고 사용하는 조성물 및 방법
WO2015198850A1 (ja) 2014-06-26 2015-12-30 住友化学株式会社 フェノール化合物の製造方法
US9125866B1 (en) 2015-01-28 2015-09-08 King Saud University Antidepressant compounds
US10377703B2 (en) * 2015-07-21 2019-08-13 Sumitomo Chemical Company, Limited Method for producing 4-(trifluoromethylsulfonyl)phenol compound
CN113853369B (zh) 2019-05-24 2025-08-22 爱尔兰790股份公司 [2-(3-氟-5-甲磺酰基苯氧基)乙基](丙基)胺的药学上可接受的盐及其用途
EP4673127A1 (en) * 2023-03-01 2026-01-07 Alexander Shulgin Research Institute, Inc. Deuterated and fluorinated empathogens

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3058980A (en) 1962-10-16 Substitution products of benzo-
US2906757A (en) 1959-09-29 Their preparation
DE1110175B (de) 1957-01-08 1961-07-06 Rhone Poulenc Sa Verfahren zur Herstellung von Benzodioxanderivaten
JPS55124781A (en) * 1979-03-20 1980-09-26 Shionogi & Co Ltd 1,4-benzdioxanesulfonamide derivative
US5236055A (en) * 1991-03-13 1993-08-17 Canadian Aging & Rehabilitation Product Development Corporation Wheel with coaxial drive system mounted in the wheelhub field of the invention
US5189171A (en) 1991-06-21 1993-02-23 American Home Products Corporation Antipsychotic benzodioxan derivatives
US5126366A (en) 1991-06-21 1992-06-30 American Home Products Corporation Aminophenoxyalkyl derivatives of benzodioxan
US5166367A (en) 1991-06-21 1992-11-24 American Home Products Corporation Antipsychotic benzodioxan derivatives
DE4135474A1 (de) 1991-10-28 1993-04-29 Bayer Ag 2-aminomethyl-chromane
US5235055A (en) 1992-09-02 1993-08-10 American Home Products Corporation Antipsychotic quinoline derivatives of benzodioxanmethylamine
US5245051A (en) 1992-09-03 1993-09-14 American Home Products Corporation Antipsychotic chroman derivatives of benzodioxanmethylamine
GB9514380D0 (en) * 1995-07-13 1995-09-13 Knoll Ag Therapeutic agents
US5684039A (en) * 1995-07-25 1997-11-04 American Home Products Corporation Chroman-2-ylmethylamino derivatives
US5663194A (en) 1995-07-25 1997-09-02 Mewshaw; Richard E. Chroman-2-ylmethylamino derivatives
AR004229A1 (es) 1995-11-06 1998-11-04 Wyeth Corp Derivados indolalquilo de benzodioxanmetilamina y su uso para preparar medicamentos
FR2791675B1 (fr) 1999-03-30 2001-05-04 Synthelabo Derives de n-[2-(4-aminophenyl) ethyl] -2,3-dihydro-1,4- benzodioxinne-2-methanamine, leur preparation et leur application en therapeutique
SE9904723D0 (sv) 1999-12-22 1999-12-22 Carlsson A Research Ab New modulators of dopamine neurotransmission II
SE9904724D0 (sv) 1999-12-22 1999-12-22 Carlsson A Research Ab New modulators of dopamine neurotransmission I
GB0007376D0 (en) 2000-03-28 2000-05-17 Knoll Ag Therapeutic agents
CA2461381A1 (en) 2001-10-04 2003-04-10 Wyeth Chroman derivatives as 5-hydroxytryptamine-6 ligands
TWI281470B (en) * 2002-05-24 2007-05-21 Elan Pharm Inc Heterocyclic compounds which inhibit leukocyte adhesion mediated by alpha4 integrins
JP2007527412A (ja) 2003-10-24 2007-09-27 エグゼリクシス， インコーポレイテッド Ｔａｏキナーゼモジュレーターおよび使用方法
JP2007536302A (ja) * 2004-05-05 2007-12-13 エフ．ホフマン−ラ　ロシュ　アーゲー ５−ｈｔ６受容体、５−ｈｔ２ａ受容体、又はその両方の調節に有用なアリールスルホニルベンゾジオキサン類
DE602005021641D1 (de) 2004-06-08 2010-07-15 Nsab, Filial Af Neurosearch Sweden Ab Neue disubstituierte phenylpiperidine und piperazine als modulatoren der dopamin-neurotransmission
AR049646A1 (es) 2004-06-16 2006-08-23 Janssen Pharmaceutica Nv Derivados de sulfamato y sulfamida utiles para el tratamiento de la epilepsia y trastornos relacionados
MY147767A (en) 2004-06-16 2013-01-31 Janssen Pharmaceutica Nv Novel sulfamate and sulfamide derivatives useful for the treatment of epilepsy and related disorders
US7713954B2 (en) 2004-09-30 2010-05-11 Roche Palo Alto Llc Compositions and methods for treating cognitive disorders
PE20061335A1 (es) 2005-04-22 2006-12-29 Wyeth Corp Compuestos derivados de benzodioxano y benzodioxolano como moduladores del receptor 5-ht2c
SE529246C2 (sv) 2005-10-13 2007-06-12 Neurosearch Sweden Ab Nya disubstituerade fenyl-piperidiner som modulatorer för dopaminneurotransmission
US8716231B2 (en) 2005-12-19 2014-05-06 Janssen Pharmaceutica Nv Use of benzo-fused heterocycle sulfamide derivatives for the treatment of pain
US20070155827A1 (en) 2005-12-19 2007-07-05 Smith-Swintosky Virginia L Use of benzo-fused heterocycle sulfamide derivatives for the treatment of depression
US8492431B2 (en) 2005-12-19 2013-07-23 Janssen Pharmaceutica, N.V. Use of benzo-fused heterocycle sulfamide derivatives for the treatment of obesity
US8691867B2 (en) 2005-12-19 2014-04-08 Janssen Pharmaceutica Nv Use of benzo-fused heterocycle sulfamide derivatives for the treatment of substance abuse and addiction
US8937096B2 (en) 2005-12-19 2015-01-20 Janssen Pharmaceutica Nv Use of benzo-fused heterocyle sulfamide derivatives for the treatment of mania and bipolar disorder
US20070155824A1 (en) 2005-12-19 2007-07-05 Smith-Swintosky Virginia L Use of benzo-fused heterocycle sulfamide derivatives for disease modification / epileptogenesis
US20070155823A1 (en) 2005-12-19 2007-07-05 Smith-Swintosky Virginia L Use of benzo-fused heterocycle sulfamide derivatives as neuroprotective agents
WO2007120596A1 (en) 2006-04-12 2007-10-25 Wyeth DIHYDRO[1,4]DIOXINO[2,3-e]INDAZOLE DERIVATIVES AS 5-HYDROXYTRYPTAMINE-6 LIGANDS
AR060493A1 (es) 2006-04-18 2008-06-18 Wyeth Corp Derivados de benzodioxano y benzodioxolano. procesos de obtencion.
TW200812573A (en) 2006-05-19 2008-03-16 Janssen Pharmaceutica Nv Co-therapy for the treatment of epilepsy and related disorders
TWI457122B (zh) 2007-07-20 2014-10-21 Orion Corp 作為用於治療周邊和中央神經系統疾病之alpha2C拮抗劑的2,3－二氫苯並[1,4]戴奧辛－2－基甲基衍生物
AU2009242095A1 (en) 2008-04-29 2009-11-05 Nsab, Filial Af Neurosearch Sweden Ab, Sverige Modulators of dopamine neurotransmission
EP2271635A1 (en) 2008-04-29 2011-01-12 NSAB, Filial af NeuroSearch Sweden AB, Sverige Modulators of dopamine neurotransmission

Similar Documents

Publication Publication Date Title
JP2011518858A5 (cg-RX-API-DMAC7.html)
RU2010141964A (ru) Модуляторы дофаминовой нейротрансмиссии
AU2002237654B2 (en) Piperazine derivatives, their preparation and their use for treating central nervous system (CNS) disorders
CN1060775C (zh) 用作神经递质重摄取抑制剂的稠合莨菪烷衍生物
RU2018130727A (ru) Органические соединения
JP2008538571A (ja) ジヒドロベンゾフラン誘導体およびその使用
RU2007139541A (ru) Производные хромана и хромена и их применение
CN1706813A (zh) 含长链脂肪酰基取代的文拉法辛前体药物及其制备方法和用途
WO2005079802A8 (en) Bipyridyl amides as modulators of metabotropic glutamate receptor-5
CN101203216A (zh) 二氢苯并呋喃衍生物及其用途
UA88719C2 (ru) Антагонисты рецепторов гистамина-3
WO2007088450A3 (en) Chromane antagonist of the h-3 receptor
JP2011518859A5 (cg-RX-API-DMAC7.html)
AU2002237654A1 (en) Piperazine derivatives, their preparation and their use for treating central nervous system (CNS) disorders
JP2008538766A (ja) 薬物乱用の処置
JP2008536946A (ja) うつ病の処置または予防のための新規の治療的組み合わせ
JP2011519839A5 (cg-RX-API-DMAC7.html)
RU2015148927A (ru) Производные изохинолина, стимулирующие нейрогенез
CN1154698A (zh) 苯并吡喃类化合物和它们作为治疗剂的用途
JP6173693B2 (ja) アリールピペラジンオピオイド受容体アンタゴニスト
CN1335835A (zh) 具有5ht1a受体活性的芳基哌啶和芳基－1,2,5,6－四氢吡啶脲衍生物
JP2012509860A5 (cg-RX-API-DMAC7.html)
RU2007142023A (ru) Пиперазин-замещенные бензотиофены для лечения психических расстройств
TW200534848A (en) 1-[2h-1-benzopyran-2-one-8-yl]-piperazine derivatives for the treatment of movement disorders
US20060223824A1 (en) Serotonergic agents